Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 safety study of NRG5051 in healthy adults and patients with Parkinson's disease or ALS
NL-OMON58838Phase 1Recruiting
- Sponsor
- NRG Therapeutics
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of NRG5051, sponsored by NRG Therapeutics. Started Nov 2025; status: recruiting.
02
Drugs
NRG5051
Beyond the preview
Go deeper on NL-OMON58838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58838.